For some opioid makers, the financial outlook is painful.
Between falling prices for many of the medicines and fast-growing litigation, a few of these companies have only modest flexibility to cope with these mounting risks, according to a new analysis by Moody’s Investor Service. And the drug maker most likely to be impacted is Endo International (ENDP).
About the Author Reprints
Thanks Ed.
Which Moody’s report is this referring to?
G
Hi Gaurav,
The report is called ‘Drug manufacturers and distributors face rising risks related to the US opioid crisis’ and was released on Nov. 30.
Regards,
ed at Pharmalot